Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 29, 2022 08:10 ET
|
Pharvaris N.V.
Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-daily dosingOrphan Drug Designation for PHA121 granted by FDARAPIDe-1, Phase 2...
Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology
March 22, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris to Participate in Upcoming March Investor Conferences
March 03, 2022 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Announces Changes to its Board of Directors
December 22, 2021 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Announces Changes to its Board of Directors
December 07, 2021 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 10, 2021 08:10 ET
|
Pharvaris N.V.
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE...
Pharvaris to Participate in Upcoming September Investor Conferences
September 03, 2021 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
July 30, 2021 08:00 ET
|
Pharvaris N.V.
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of...
Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
July 09, 2021 18:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...